Loading...

ONC BEONE MEDICINES LTD Investments/Divestments 8-K Filing

BN M

NC

BEONE MEDICINES LTD

(ONC)

2023 8-K

Show Summary

Summary

Financial Report Filing

Royalty Agreement

Financial Statements

Equity Offerings

Financial Statements

Financial Statements

Financial Results

2025 Income Guidance

Credit Facility Agreement

Patent Settlement

Director Passing

SEC Comment Letter

Board Appointment

Financial Results and Busin...

Appointment of CFO

Annual Meeting Approval

Financial Results and Busin...

Financial Report

Approval for Tislelizumab a...

Resignation and Appointment

FDA Approval for TEVIMBRA

Financial Results and Busin...

Director Resignation and Ap...

Consulting Agreement Renewal

Financial Results and Busin...

NICE Recommendation for BRU...

Regulatory Updates

Settlement and Termination ...

Product Approvals

Amendment to Articles of In...

Announcement of Data Presen...

Approval for BRUKINSA in China

Financial Results and Corpo...

Financial Report

Positive Trial Results

Amended Independent Directo...

Financial Results and Busin...

Share Purchase Agreement wi...

BeiGene announces inclusion...

External Links:

BeiGene announced that its PD-1 inhibitor tislelizumab has been included in China's National Reimbursement Drug List for four new indications, and its Bruton's tyrosine kinase inhibitor BRUKINSA has been approved by the FDA for the treatment of chronic lymphocytic leukemia.

AI Assistant

BEONE MEDICINES LTD

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.